Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51

1.

PATZ1 Is Overexpressed in Pediatric Glial Tumors and Correlates with Worse Event-Free Survival in High-grade Gliomas.

Passariello A, Errico ME, Donofrio V, Maestrini M, Zerbato A, Cerchia L, Capasso M, Capasso M, Fedele M.

Cancers (Basel). 2019 Oct 11;11(10). pii: E1537. doi: 10.3390/cancers11101537.

2.

Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing.

Passariello M, Camorani S, Vetrei C, Cerchia L, De Lorenzo C.

Cancers (Basel). 2019 Aug 29;11(9). pii: E1268. doi: 10.3390/cancers11091268.

3.

Proneural-Mesenchymal Transition: Phenotypic Plasticity to Acquire Multitherapy Resistance in Glioblastoma.

Fedele M, Cerchia L, Pegoraro S, Sgarra R, Manfioletti G.

Int J Mol Sci. 2019 Jun 4;20(11). pii: E2746. doi: 10.3390/ijms20112746. Review.

4.

Dual Oncogenic/Anti-Oncogenic Role of PATZ1 in FRTL5 Rat Thyroid Cells Transformed by the Ha-RasV12 Oncogene.

Vitiello M, Palma G, Monaco M, Bello AM, Camorani S, Francesca P, Rea D, Barbieri A, Chiappetta G, Vita G, Cerchia L, Arra C, Fedele M.

Genes (Basel). 2019 Feb 9;10(2). pii: E127. doi: 10.3390/genes10020127.

5.

Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFRβ aptamer.

Camorani S, Hill BS, Collina F, Gargiulo S, Napolitano M, Cantile M, Di Bonito M, Botti G, Fedele M, Zannetti A, Cerchia L.

Theranostics. 2018 Oct 6;8(18):5178-5199. doi: 10.7150/thno.27798. eCollection 2018.

6.

TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities.

Camorani S, Fedele M, Zannetti A, Cerchia L.

Pharmaceuticals (Basel). 2018 Nov 13;11(4). pii: E123. doi: 10.3390/ph11040123. Review.

7.

Aptamers: Promising Tools for Cancer Diagnosis and Therapy.

Cerchia L.

Cancers (Basel). 2018 May 3;10(5). pii: E132. doi: 10.3390/cancers10050132.

8.

Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κB.

Camorani S, Cerchia L, Fedele M, Erba E, D'Incalci M, Crescenzi E.

Oncotarget. 2018 Apr 13;9(28):19929-19944. doi: 10.18632/oncotarget.24961. eCollection 2018 Apr 13.

9.

Loss of One or Two PATZ1 Alleles Has a Critical Role in the Progression of Thyroid Carcinomas Induced by the RET/PTC1 Oncogene.

Monaco M, Palma G, Vitiello M, Capiluongo A, D'Andrea B, Vuttariello E, Luciano A, Cerchia L, Chiappetta G, Arra C, Fusco A, Fedele M.

Cancers (Basel). 2018 Mar 27;10(4). pii: E92. doi: 10.3390/cancers10040092.

10.

Oligonucleotide aptamers against tyrosine kinase receptors: Prospect for anticancer applications.

Camorani S, Crescenzi E, Fedele M, Cerchia L.

Biochim Biophys Acta Rev Cancer. 2018 Apr;1869(2):263-277. doi: 10.1016/j.bbcan.2018.03.003. Epub 2018 Mar 21. Review.

PMID:
29574128
11.

The POZ/BTB and AT-Hook Containing Zinc Finger 1 (PATZ1) Transcription Regulator: Physiological Functions and Disease Involvement.

Fedele M, Crescenzi E, Cerchia L.

Int J Mol Sci. 2017 Nov 24;18(12). pii: E2524. doi: 10.3390/ijms18122524. Review.

12.

The Epithelial-to-Mesenchymal Transition in Breast Cancer: Focus on Basal-Like Carcinomas.

Fedele M, Cerchia L, Chiappetta G.

Cancers (Basel). 2017 Sep 30;9(10). pii: E134. doi: 10.3390/cancers9100134. Review.

13.

PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype.

Guadagno E, Vitiello M, Francesca P, Calì G, Caponnetto F, Cesselli D, Camorani S, Borrelli G, Califano M, Cappabianca P, Arra C, Crescenzi E, Cerchia L, De Caro MLDB, Fedele M.

Oncotarget. 2017 Jul 25;8(35):59282-59300. doi: 10.18632/oncotarget.19546. eCollection 2017 Aug 29.

14.

Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.

Camorani S, Hill BS, Fontanella R, Greco A, Gramanzini M, Auletta L, Gargiulo S, Albanese S, Lucarelli E, Cerchia L, Zannetti A.

Theranostics. 2017 Aug 22;7(14):3595-3607. doi: 10.7150/thno.18974. eCollection 2017.

15.

Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier.

Monaco I, Camorani S, Colecchia D, Locatelli E, Calandro P, Oudin A, Niclou S, Arra C, Chiariello M, Cerchia L, Comes Franchini M.

J Med Chem. 2017 May 25;60(10):4510-4516. doi: 10.1021/acs.jmedchem.7b00527. Epub 2017 May 10.

PMID:
28471660
16.

Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancers.

Camorani S, Crescenzi E, Gramanzini M, Fedele M, Zannetti A, Cerchia L.

Sci Rep. 2017 Apr 20;7:46659. doi: 10.1038/srep46659.

17.

PATZ1 expression correlates positively with BAX and negatively with BCL6 and survival in human diffuse large B cell lymphomas.

Franco R, Scognamiglio G, Valentino E, Vitiello M, Luciano A, Palma G, Arra C, La Mantia E, Panico L, Tenneriello V, Pinto A, Frigeri F, Capobianco G, Botti G, Cerchia L, De Chiara A, Fedele M.

Oncotarget. 2016 Sep 13;7(37):59158-59172. doi: 10.18632/oncotarget.10993.

18.

PATZ1 is a target of miR-29b that is induced by Ha-Ras oncogene in rat thyroid cells.

Vitiello M, Valentino T, De Menna M, Crescenzi E, Francesca P, Rea D, Arra C, Fusco A, De Vita G, Cerchia L, Fedele M.

Sci Rep. 2016 Apr 29;6:25268. doi: 10.1038/srep25268.

19.

A novel antagonist of CXCR4 prevents bone marrow-derived mesenchymal stem cell-mediated osteosarcoma and hepatocellular carcinoma cell migration and invasion.

Fontanella R, Pelagalli A, Nardelli A, D'Alterio C, Ieranò C, Cerchia L, Lucarelli E, Scala S, Zannetti A.

Cancer Lett. 2016 Jan 1;370(1):100-7. doi: 10.1016/j.canlet.2015.10.018. Epub 2015 Oct 27.

PMID:
26517945
20.

Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.

Camorani S, Crescenzi E, Colecchia D, Carpentieri A, Amoresano A, Fedele M, Chiariello M, Cerchia L.

Oncotarget. 2015 Nov 10;6(35):37570-87. doi: 10.18632/oncotarget.6066.

Supplemental Content

Loading ...
Support Center